Aurinia Pharmaceuticals (NASDAQ:AUPH) Stock Price Down 3.6% – Here’s Why
by Doug Wharley · The Cerbat GemShares of Aurinia Pharmaceuticals Inc (NASDAQ:AUPH – Get Free Report) (TSE:AUP) traded down 3.6% during trading on Friday . The stock traded as low as $15.01 and last traded at $15.38. 211,006 shares were traded during trading, a decline of 78% from the average session volume of 979,646 shares. The stock had previously closed at $15.95.
Analyst Ratings Changes
Several equities research analysts have issued reports on AUPH shares. Bloom Burton cut Aurinia Pharmaceuticals from a “moderate buy” rating to a “hold” rating in a research note on Wednesday, November 5th. Jefferies Financial Group raised Aurinia Pharmaceuticals from a “hold” rating to a “buy” rating and raised their price objective for the stock from $10.00 to $21.00 in a research report on Friday, November 7th. Royal Bank Of Canada reaffirmed a “sector perform” rating and issued a $15.00 target price (up previously from $9.00) on shares of Aurinia Pharmaceuticals in a research report on Wednesday, November 5th. Weiss Ratings reiterated a “hold (c)” rating on shares of Aurinia Pharmaceuticals in a research report on Wednesday, October 8th. Finally, Leerink Partners lowered shares of Aurinia Pharmaceuticals from an “outperform” rating to a “market perform” rating and upped their price objective for the stock from $15.00 to $16.00 in a report on Wednesday, December 3rd. Two equities research analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $17.25.
Get Our Latest Stock Report on Aurinia Pharmaceuticals
Aurinia Pharmaceuticals Stock Performance
The company has a quick ratio of 5.17, a current ratio of 5.76 and a debt-to-equity ratio of 0.15. The firm has a 50-day simple moving average of $15.19 and a 200 day simple moving average of $12.24. The company has a market cap of $2.00 billion, a price-to-earnings ratio of 27.20 and a beta of 1.46.
Aurinia Pharmaceuticals (NASDAQ:AUPH – Get Free Report) (TSE:AUP) last announced its quarterly earnings data on Tuesday, November 4th. The biotechnology company reported $0.23 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.16 by $0.07. The company had revenue of $73.47 million for the quarter, compared to analysts’ expectations of $67.70 million. Aurinia Pharmaceuticals had a net margin of 29.28% and a return on equity of 25.19%. On average, sell-side analysts predict that Aurinia Pharmaceuticals Inc will post 0.11 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Aurinia Pharmaceuticals
Institutional investors have recently made changes to their positions in the stock. Ieq Capital LLC acquired a new position in Aurinia Pharmaceuticals during the first quarter worth about $266,000. Vident Advisory LLC acquired a new stake in shares of Aurinia Pharmaceuticals during the first quarter valued at about $232,000. MAI Capital Management bought a new position in Aurinia Pharmaceuticals in the 1st quarter worth about $39,000. Royal Bank of Canada grew its stake in shares of Aurinia Pharmaceuticals by 65.3% in the first quarter. Royal Bank of Canada now owns 367,661 shares of the biotechnology company’s stock worth $2,956,000 after purchasing an additional 145,179 shares in the last quarter. Finally, AQR Capital Management LLC lifted its stake in shares of Aurinia Pharmaceuticals by 8.7% in the 1st quarter. AQR Capital Management LLC now owns 503,543 shares of the biotechnology company’s stock worth $4,048,000 after acquiring an additional 40,380 shares during the period. 36.83% of the stock is currently owned by hedge funds and other institutional investors.
Aurinia Pharmaceuticals Company Profile
Aurinia Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company focused on developing and commercializing therapies for autoimmune diseases. The company’s proprietary molecule, voclosporin, is designed to selectively inhibit calcineurin and reduce inflammation associated with autoimmune responses. Aurinia operates research and development facilities in Canada and the United States, leveraging collaborations with academic institutions and contract research organizations to advance its clinical pipeline.
The company’s lead product, voclosporin (marketed as LUPKYNIS), received approval from the U.S.